摘要
免疫组织化学(IHC)是一种在所有病理实验室都可行的,测试范围广,成本低和辅助快的技术。这种方法通常用于诊断目的,但一些研究将它作为替代试验来调查不同的免疫组化抗体在非小细胞肺癌(NSCLC),特别是表皮生长因子受体(EGFR)基因突变,间变性淋巴瘤激酶(ALK)基因和ROS1重排中预测性生物标志物的测定的中敏感性和特异性。这篇综述讨论了免疫组化表达与传统分子技术一致性的比较,确定遗传学改变和NSCLC预测值。总之,关于抗ALK和ROS1的特异性抗体的敏感性和特异性的数据十分一致,是时候相信IHC至少在临床上能作为一个有效的筛查工具来识别重组肿瘤患者。另一方面,针对EGFR的突变特异性抗体表现出好的特异性但敏感性却低于平均水平,因此将它们作为指标性预测生物标记物就要很小心了。本文还对抗BRAF, RET, HER2和c-MET抗体的初步经验给出了简要评价。
关键词: 间变性淋巴瘤激酶,表皮生长因子受体,基因突变,,免疫组织化学,肺癌,分子生物学,ROS1
Current Drug Targets
Title:Does Immunohistochemistry Represent a Robust Alternative Technique in Determining Drugable Predictive Gene Alterations in Non-Small Cell Lung Cancer?
Volume: 18 Issue: 1
Author(s): Giulio Rossi, Moira Ragazzi, Ione Tamagnini, Maria C. Mengoli, Giada Vincenzi, Fausto Barbieri, Silvia Piccioli and Alessandra Bisagni, Tiziana Vavala, Luisella Righi, Silvia Novello, Francesco Gelsomino, Marcello Tiseo
Affiliation:
关键词: 间变性淋巴瘤激酶,表皮生长因子受体,基因突变,,免疫组织化学,肺癌,分子生物学,ROS1
摘要: Immunohistochemistry (IHC) is a widely-tested, low-cost and rapid ancillary technique available in all laboratories of pathology. This method is generally used for diagnostic purposes, but several studies have investigated the sensitivity and specificity of different immunohistochemical antibodies as a surrogate test in the determination of predictive biomarkers in non-small cell lung cancer (NSCLC), particularly for Epidermal Growth Factor Receptor (EGFR) gene mutations, Anaplastic Lymphoma Kinase (ALK) gene and ROS1 rearrangements. In this review, a critical examination of the works comparing the consistency of IHC expression and conventional molecular techniques to identify genetic alterations with predictive value in NSCLC is discussed. Summarizing, data on sensitivity and specificity of antibodies against ALK and ROS1 are very consistent and time has come to trust in IHC at least as a cost-effective screening tool to identify patients with rearranged tumors in clinical practice. On the other hand, mutant-specific antibodies against EGFR demonstrate a good specificity but a lowto- fair sensitivity, raising some cautions on their employment as robust predictive biomarkers. A brief comment on preliminary experiences with antibodies against BRAF, RET, HER2 and c-MET is also included.
Export Options
About this article
Cite this article as:
Giulio Rossi, Moira Ragazzi, Ione Tamagnini, Maria C. Mengoli, Giada Vincenzi, Fausto Barbieri, Silvia Piccioli and Alessandra Bisagni, Tiziana Vavala, Luisella Righi, Silvia Novello, Francesco Gelsomino, Marcello Tiseo , Does Immunohistochemistry Represent a Robust Alternative Technique in Determining Drugable Predictive Gene Alterations in Non-Small Cell Lung Cancer?, Current Drug Targets 2017; 18 (1) . https://dx.doi.org/10.2174/1389450116666150330114441
DOI https://dx.doi.org/10.2174/1389450116666150330114441 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Current Developments of Coumarin Compounds in Medicinal Chemistry
Current Pharmaceutical Design MDM4 (MDMX) and its Transcript Variants
Current Genomics Suppressing Glioblastoma Stem Cell Function by Aldehyde Dehydrogenase Inhibition with Chloramphenicol or Disulfiram as a New Treatment Adjunct: A Hypothesis
Current Stem Cell Research & Therapy Targeting SphK1 as a New Strategy against Cancer
Current Drug Targets Is the Expression of Deoxynucleoside Kinases and 5'-nucleotidases in Animal Tissues Related to the Biological Effects of Nucleoside Analogs?
Current Medicinal Chemistry Antiviral Immunotherapy for Mosquito-Borne Flaviviruses: A Review of Current Status
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Voltage-Gated Ion Channels, New Targets in Anti-Cancer Research
Recent Patents on Anti-Cancer Drug Discovery Membrane Permeable Lipophilic Cations as Mitochondrial Directing Groups
Current Topics in Medicinal Chemistry lncRNAs as Potential Targets in Small Cell Lung Cancer: MYC -dependent Regulation
Anti-Cancer Agents in Medicinal Chemistry Potassium Channels: Novel Emerging Biomarkers and Targets for Therapy in Cancer
Recent Patents on Anti-Cancer Drug Discovery Oncotargets in Different Renal Cancer Subtypes
Current Drug Targets ATRA Entrapped in DSPC Liposome Enhances Anti-metastasis Effect on Lung and Liver During B16F10 Cell Line Metastasis in C57BL6 Mice
Anti-Cancer Agents in Medicinal Chemistry Targeting the Akt Kinase to Modulate Survival, Invasiveness and Drug Resistance of Cancer Cells
Current Medicinal Chemistry Mechanisms of Action of DNA-Damaging Anticancer Drugs in Treatment of Carcinomas: Is Acute Apoptosis an “Off-Target” Effect?
Mini-Reviews in Medicinal Chemistry Overview of SLC22A and SLCO Families of Drug Uptake Transporters in the Context of Cancer Treatments
Current Drug Metabolism The Impact of 5-Substituted Uracil Derivatives on Immortalized Embryo Lung Cells
Letters in Drug Design & Discovery Pisosterol Induces G2/M Cell Cycle Arrest and Apoptosis via the ATM/ATR Signaling Pathway in Human Glioma Cells
Anti-Cancer Agents in Medicinal Chemistry Amino Acid Degrading Enzymes and their Application in Cancer Therapy
Current Medicinal Chemistry Combining Anti-Epidermal Growth Factor Receptor (EGFR) and Anti-Angiogenic Strategies in Advanced NSCLC: We Should have Known Better...
Current Pharmaceutical Design RepurposeVS: A Drug Repurposing-Focused Computational Method for Accurate Drug-Target Signature Predictions
Combinatorial Chemistry & High Throughput Screening